Loading
Life sciences · Journal article
Frontiers in Genetics · October 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Liver involvement in ovarian cancer is often treated as a single clinical entity, although liver-surface implants and parenchymal deposits occupy different anatomical settings and may not share the same molecular history. Primary-tumor profiling is informative, but can miss lesion-specific evolution, treatment-associated cell states, and microenvironmental structure. This Mini Review examines how germline susceptibility, somatic change, spatial biology, and artificial intelligence might be combined in high-grade serous ovarian cancer. The central task is not simply outcome prediction. It is to distinguish constitutional from tumor-acquired variation, retain lesion identity and treatment timing, and relate molecular programs to defined spatial compartments. Current data support marked clonal and microenvironmental heterogeneity in ovarian cancer, but direct molecular evidence from hepatic lesions remains sparse. AI-based integration is therefore best viewed as a way to formulate and test reproducible hypotheses, rather than as a validated route to select liver-directed therapy. Paired sampling, orthogonal assays, patient-level validation, and decision-specific clinical endpoints will be needed before these models can influence management.